1,125 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by GAMMA Investing LLC

GAMMA Investing LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,125 shares of the medical research company’s stock, valued at approximately $83,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its holdings in Exact Sciences by 94.0% during the 4th quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock worth $100,681,000 after acquiring an additional 659,235 shares in the last quarter. EFG Asset Management Americas Corp. grew its holdings in Exact Sciences by 14.6% during the 4th quarter. EFG Asset Management Americas Corp. now owns 3,780 shares of the medical research company’s stock worth $280,000 after acquiring an additional 482 shares in the last quarter. Hussman Strategic Advisors Inc. grew its holdings in Exact Sciences by 400.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 31,500 shares of the medical research company’s stock worth $2,330,000 after acquiring an additional 25,200 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Exact Sciences by 0.9% during the 4th quarter. Handelsbanken Fonder AB now owns 34,200 shares of the medical research company’s stock worth $2,530,000 after acquiring an additional 300 shares in the last quarter. Finally, CWM LLC grew its holdings in Exact Sciences by 8.2% during the 4th quarter. CWM LLC now owns 7,709 shares of the medical research company’s stock worth $570,000 after acquiring an additional 583 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on EXAS shares. TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. Citigroup restated a “buy” rating and issued a $100.00 price target on shares of Exact Sciences in a report on Wednesday, April 3rd. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity Group lowered their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.44.

Insider Activity

In other news, General Counsel James Herriott sold 421 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $25,862.03. Following the transaction, the general counsel now owns 6,494 shares of the company’s stock, valued at approximately $398,926.42. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, General Counsel James Herriott sold 421 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $25,862.03. Following the sale, the general counsel now directly owns 6,494 shares in the company, valued at approximately $398,926.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director D Scott Coward sold 706 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the completion of the sale, the director now owns 43,122 shares in the company, valued at $2,652,003. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,113 shares of company stock valued at $4,165,273. 1.30% of the stock is currently owned by insiders.

Exact Sciences Trading Down 0.1 %

Shares of EXAS opened at $58.78 on Tuesday. Exact Sciences Co. has a 52-week low of $56.05 and a 52-week high of $100.77. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. The firm’s fifty day moving average is $63.40 and its two-hundred day moving average is $64.89. The stock has a market cap of $10.81 billion, a PE ratio of -51.56 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. The firm had revenue of $646.89 million for the quarter, compared to analysts’ expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.72) EPS. Research analysts forecast that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.